Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2008-04-11
2010-12-07
Belyavskyi, Michail A (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C530S387100
Reexamination Certificate
active
07846434
ABSTRACT:
Immunoglycoproteins, including antibodies, with improved ADCC and altered glycosylation patterns are provided. Also provided are cell culturing methods and media for producing such immunoglycoproteins, and therapeutic uses of such immunoglycoproteins.
REFERENCES:
patent: 5605690 (1997-02-01), Jacobs et al.
patent: 5914111 (1999-06-01), Wallner et al.
patent: 6737056 (2004-05-01), Presta
patent: 2002/0199213 (2002-12-01), Tomizuka et al.
patent: 2003/0031667 (2003-02-01), Deo et al.
patent: 2003/0118592 (2003-06-01), Ledbetter et al.
patent: 2003/0133939 (2003-07-01), Ledbetter et al.
patent: 2003/0194404 (2003-10-01), Greenfeder et al.
patent: 2004/0053366 (2004-03-01), Lo et al.
patent: 2005/0037421 (2005-02-01), Honda et al.
patent: 2005/0095700 (2005-05-01), Budzowski et al.
patent: 2005/0136049 (2005-06-01), Ledbetter et al.
patent: 2006/0127404 (2006-06-01), Huang et al.
patent: 2007/0020260 (2007-01-01), Presta
patent: 2007/0059306 (2007-03-01), Grosmaire et al.
patent: 404097 (1990-12-01), None
patent: WO-91/10741 (1991-07-01), None
patent: WO-92/01047 (1992-01-01), None
patent: WO-93/11161 (1993-06-01), None
patent: WO-96/34096 (1996-10-01), None
patent: WO-98/24893 (1998-06-01), None
patent: WO-91/17271 (1999-11-01), None
patent: WO-2004/002424 (2004-01-01), None
patent: WO-2005/081687 (2005-09-01), None
patent: WO 2007/028144 (2007-03-01), None
patent: WO-2007/048122 (2007-04-01), None
patent: WO 2007014278 (2007-05-01), None
patent: WO-2007/146968 (2007-06-01), None
patent: WO 2007/121354 (2007-10-01), None
Biocca et al., Expression and targeting of intracellular antibodies in mammalian cells,EMBO J., 9: 101-8 (1990).
Bird et al., Single-chain antigen-binding proteins,Science 242: 423-6 (1988).
Bruggemann et al., Designer mice: the production of human antibody repertoires in transgenic animals.,Year in Immuno., 7:33-40 (1993).
Castanospermine from Castanospermum australe seeds. http://www.sigmaaldrich.com/sigma/product%20information%20sheet/c3784pis.pdf (2005).
Caton et al., Influenza virus hemagglutinin-specific antibodies isolated from a combinatorial expression library are closely related to the immune response of the donor,Proc. Natl. Acad. Sci.87:6450-4 (1990).
Chang et al., Targeted gene therapy with CD40Ig to induce long-term acceptance of liver allografts,Surgery, 132: 149-56 (2002).
Chothia et al., Canonical structures for the hypervariable regions of immunoglobulins,J. Mol. Bio.196: 901-917 (1987).
Co at el., A humanized antibody specific for the platelet integrin gpIIb/IIIa,J. Immunol.152:2968-76 (1994).
Colby et al., Potent inhibition of huntingtin aggregation and cytotoxicity by a disulfide bond-free single-domain intracellular antibody,Proc. Natl. Acad. Sci.101:17616-21 (2004).
Cortez-Retamozo et al., Efficient cancer therapy with a nanobody-based conjugate.,Cancer Research, 64:2853-57 (2004).
Desmyter et al., Antigen specificity and high affinity binding provided by one single loop of a camel single-domain antibody,J. Biol. Chem.276: 26285-90 (2001).
Elbein et al., Glycosidase inhibitors: Inhibitors of N-linked oligosaccharide processing.FASEB J.5: 3055-63 (1991).
Ewert et al., Biophysical properties of camelid V(HH) domains compared to those of human V(H)3 domains,Biochemistry, 41:3628-36 (2002).
Ferrara et al., Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme localization domain and co-expression of heterologous beta1, 4-N-acetylglucosaminyltransferase III and Golgi alpha-mannosidase II,Biotechnol Bioeng., 93: 851-861 (2006).
Genbank Accession No. BC031992,Homo sapiensFc fragment of IgG, low affinity IIb, receptor (CD32), 2006.
Genbank Accession No. BC032634,Homo sapiensFc fragment of IgG, high affinity Ia, receptor (CD64), 2006.
Genbank Accession No. NM021642,Homo sapiensFc fragment of IgG, low affinity IIa, receptor (CD32)(FCGR2A), 2008.
Genbank Accession No. X07934, Human mRNA for Fc gamma receptor (FcRIII, CD16, FcR-lo), 2004.
Gruber et al., Efficient tumor cell lysis mediated by a bispecific single chain antibody expressed inEscherichia coli, J. Immunol.152: 5368 (1994).
Hashim et al., Role of processing of N-linked oligosaccharides in control of immunoglobulin secretion from rat hybridomas.Mol. lmmunol.24: 1087-96 (1987).
Hodoniczky et al., Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro,Biotechnol. Prog., 21: 1644-1652 (2005).
Hollinger et al., “Diabodies”: small bivalent and bispecific antibody fragments,Proc. Natl. Acad. Sci.90: 6444-8 (1993).
Hu et al., Targeting tissue factor on tumor vascular endothelial cells and tumor cells for immunotherapy in mouse models of prostatic cancer,Proc. Natl. Acad. Sci.98, 12180-5 (2001).
Huston et al., Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced inEscherichia coli, Proc. Natl. Acad. Sci.85:5879-83 (1988).
Jakobovits et al., Analysis of homozygous mutant chimeric mice: deletion of the immunoglobulin heavy-chain joining region blocks B-cell development and antibody production,Proc. Natl. Acad. Sci.90:2551 (1993).
Jakobovits et al., Germ-line transmission and expression of a human-derived yeast artificial chromosome,Nature, 362:255-8 (1993).
Jones et al., Replacing the complementarity-determining regions in a human antibody with those from a mouse,Nature, 321:522-525 (1986).
Kanda et al., Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types.Glycobiology. 17: 104-18 (2006).
Kettleborough, et al., Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation,Protein Eng.4:773-83 (1991).
Kim et al., Targeting the IL-15 receptor with an antagonist IL-15 mutant/Fc gamma2a protein blocks delayed-type hypersensitivity,J. Immunol.160, 5742-8 (1998).
Landolfi, A chimeric IL-2/Ig molecule possesses the functional activity of both proteins,J. lmmunol.146, 915-9 (1991).
Morrison et al., Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains,Proc. Natl. Acad. Sci., 81: 6851-55 (1984).
Morrison et al., Genetically engineered antibody molecules ,Adv. lmmunol., 44: 65-92 (1988).
Neri et al., Basal cell and basosquamous carcinomas of the external ear. Immunohistochemical study,J. Mol. Biol., 246: 367-73 (1995).
Olafsen et al., Characterization of engineered anti-p185HER-2 (scFv-CH3)2 antibody fragments (minibodies) for tumor targeting,Protein Eng. Des Sel. 17: 315-23 (2004).
Padlan, A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties,Molec. lmmun.28:489-98 (1991).
Padlan, Anatomy of the antibody molecule,Molec. Immun.31:169-217 (1994).
Rosnet et al., Expression and signal transduction of the FLT3 tyrosine kinase receptor,Acta. Haemato., 95:218-23, (1996).
Rothman et al., Antibody-dependent cytotoxicity mediated by natural killer calls is enhanced by castanospermine-induced alterations of IgG glycosylation.Mol. lmmunol.26:1113-23 (1989).
Sayegh et al., CD28-B7 blockade after alloantigenic challenge in vivo inhibits Th1 cytokines but spares Th2,J. Exp. Med., 181, 1869-74 (1995).
Sburlati et al., Synthesis of bisected glycoforms of recombinant IFN-beta by overexpression of beta-1,4-N-acetylglucosaminyltransferase III in Chinese hamster ovary cells,Biotechnol. Prog., 14: 189-192 (1998).
Scatchard et al.,Ann N.Y. Acad. Sci., 51:660 (1949).
Schoonjans et al., Fab chains as an efficient heterodimerization scaffold for the production of recombinant bispecific and trispecific antibody derivatives,J. Immunol., 165: 7050-57 (2000).
Shields et al., Lack of Fucose on Human IgG1 N-Linked Oligosaccharide Improves Binding to Human FcγRIII and Antibody-dependent Cellular Toxicity,J. Biol. Chem.277: 26733-26740 (2002).
Shinkawa et al., The Absence of Fucose but Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Hum
Baum Peter Robert
Espling Erik Stephen
Thompson Peter Armstrong
Belyavskyi Michail A
Sleath Janet
Speckman Law Group PLLC
Trubion Pharmaceuticals, Inc.
LandOfFree
Materials and methods for improved immunoglycoproteins does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Materials and methods for improved immunoglycoproteins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Materials and methods for improved immunoglycoproteins will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4176193